Adjunctive therapy for the treatment of primary generalized tonic-clonic seizures: focus on once-daily lamotrigine

Linda Steinbaugh, Jerzy P SzaflarskiDepartment of Neurology and Cincinnati Epilepsy Center, University of Cincinnati Academic Health Center, Cincinnati, Ohio, USAAbstract: Idiopathic generalized epilepsies are frequently encountered by neurologists, and providing an accurate diagnosis and effective...

Full description

Bibliographic Details
Main Authors: Linda Steinbaugh, Jerzy P Szaflarski
Format: Article
Language:English
Published: Dove Medical Press 2010-11-01
Series:Drug Design, Development and Therapy
Online Access:http://www.dovepress.com/adjunctive-therapy-for-the-treatment-of-primary-generalized-tonic-clon-a5678
id doaj-f5db22d7f0c34b88ad05d145de50f62f
record_format Article
spelling doaj-f5db22d7f0c34b88ad05d145de50f62f2020-11-24T22:48:15ZengDove Medical PressDrug Design, Development and Therapy1177-88812010-11-012010default337342Adjunctive therapy for the treatment of primary generalized tonic-clonic seizures: focus on once-daily lamotrigineLinda SteinbaughJerzy P SzaflarskiLinda Steinbaugh, Jerzy P SzaflarskiDepartment of Neurology and Cincinnati Epilepsy Center, University of Cincinnati Academic Health Center, Cincinnati, Ohio, USAAbstract: Idiopathic generalized epilepsies are frequently encountered by neurologists, and providing an accurate diagnosis and effective treatment(s) are the necessary components of successful patient care. With the introduction of new antiepileptic medications, physicians are better equipped for this goal. The immediate-release formulation of lamotrigine (LTG-IR) has been approved for primary generalized tonic-clonic seizures since 2006. The extended-release formulation of lamotrigine (LTG-XR) was approved for adjunctive therapy in patients with primary generalized tonic-clonic seizures in 2010. Although its exact mechanism of action is not yet fully elucidated, studies have demonstrated multiple possible pathways. Although both the LTG-IR and LTG-XR formulations have similar side effects and are generally well tolerated, LTG-XR may be preferable for its ease of use, which may increase patient compliance and decrease fluctuations in serum drug levels. The ease of conversion between the formulations also makes lamotrigine an attractive treatment option for patients with primary generalized tonic-clonic seizures. LTG-IR has demonstrated efficacy in treatment-resistant idiopathic generalized epilepsies in both adults and children. Although there are still some questions regarding all possible applications of LTG-XR, as further research is being done, it is clear that LTG-XR may hold some advantages when compared with other anticonvulsants.Keywords: lamotrigine, GTC, IGE, generalized seizures, treatment http://www.dovepress.com/adjunctive-therapy-for-the-treatment-of-primary-generalized-tonic-clon-a5678
collection DOAJ
language English
format Article
sources DOAJ
author Linda Steinbaugh
Jerzy P Szaflarski
spellingShingle Linda Steinbaugh
Jerzy P Szaflarski
Adjunctive therapy for the treatment of primary generalized tonic-clonic seizures: focus on once-daily lamotrigine
Drug Design, Development and Therapy
author_facet Linda Steinbaugh
Jerzy P Szaflarski
author_sort Linda Steinbaugh
title Adjunctive therapy for the treatment of primary generalized tonic-clonic seizures: focus on once-daily lamotrigine
title_short Adjunctive therapy for the treatment of primary generalized tonic-clonic seizures: focus on once-daily lamotrigine
title_full Adjunctive therapy for the treatment of primary generalized tonic-clonic seizures: focus on once-daily lamotrigine
title_fullStr Adjunctive therapy for the treatment of primary generalized tonic-clonic seizures: focus on once-daily lamotrigine
title_full_unstemmed Adjunctive therapy for the treatment of primary generalized tonic-clonic seizures: focus on once-daily lamotrigine
title_sort adjunctive therapy for the treatment of primary generalized tonic-clonic seizures: focus on once-daily lamotrigine
publisher Dove Medical Press
series Drug Design, Development and Therapy
issn 1177-8881
publishDate 2010-11-01
description Linda Steinbaugh, Jerzy P SzaflarskiDepartment of Neurology and Cincinnati Epilepsy Center, University of Cincinnati Academic Health Center, Cincinnati, Ohio, USAAbstract: Idiopathic generalized epilepsies are frequently encountered by neurologists, and providing an accurate diagnosis and effective treatment(s) are the necessary components of successful patient care. With the introduction of new antiepileptic medications, physicians are better equipped for this goal. The immediate-release formulation of lamotrigine (LTG-IR) has been approved for primary generalized tonic-clonic seizures since 2006. The extended-release formulation of lamotrigine (LTG-XR) was approved for adjunctive therapy in patients with primary generalized tonic-clonic seizures in 2010. Although its exact mechanism of action is not yet fully elucidated, studies have demonstrated multiple possible pathways. Although both the LTG-IR and LTG-XR formulations have similar side effects and are generally well tolerated, LTG-XR may be preferable for its ease of use, which may increase patient compliance and decrease fluctuations in serum drug levels. The ease of conversion between the formulations also makes lamotrigine an attractive treatment option for patients with primary generalized tonic-clonic seizures. LTG-IR has demonstrated efficacy in treatment-resistant idiopathic generalized epilepsies in both adults and children. Although there are still some questions regarding all possible applications of LTG-XR, as further research is being done, it is clear that LTG-XR may hold some advantages when compared with other anticonvulsants.Keywords: lamotrigine, GTC, IGE, generalized seizures, treatment
url http://www.dovepress.com/adjunctive-therapy-for-the-treatment-of-primary-generalized-tonic-clon-a5678
work_keys_str_mv AT lindasteinbaugh adjunctivetherapyforthetreatmentofprimarygeneralizedtonicclonicseizuresfocusononcedailylamotrigine
AT jerzypszaflarski adjunctivetherapyforthetreatmentofprimarygeneralizedtonicclonicseizuresfocusononcedailylamotrigine
_version_ 1725678878842683392